平安低碳经济混合A（009878）基金经理为何杰。 截至发稿，何杰累计任职时间7年174天，现任基金资产总规模21.85亿元，任职期间最佳基金回报 222.53%， 任职期间最差基金回报-3.75%。 从基金十大重仓股角度 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 从春立医疗十大流通股东角度 数据显示，平安基金旗下1只基金位居春立医疗十大流通股东。平安低碳经济混合A（009878）二季度 增持277万股，持有股数377万股，占流通股的比例为0.98%。根据测算，今日浮盈赚取约452.4万元。 平安低碳 ...

Core Viewpoint - Spring Medical has shown significant stock performance with a year-to-date increase of 89.95%, indicating strong market interest and potential growth in the orthopedic medical device sector [1][2]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing. The company specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1]. - The main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal internal fixation systems. The company exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [1]. Financial Performance - For the first half of 2025, Spring Medical reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27%. The net profit attributable to shareholders was 114 million yuan, with a year-on-year increase of 44.85% [2]. - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [2]. - Notable institutional shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with significant changes in holdings among the top ten circulating shareholders [3].

来源：新浪证券-红岸工作室 9月29日，春立医疗跌1.25%，成交额4610.74万元。两融数据显示，当日春立医疗获融资买入额690.83 万元，融资偿还311.02万元，融资净买入379.81万元。截至9月29日，春立医疗融资融券余额合计 3322.38万元。 融资方面，春立医疗当日融资买入690.83万元。当前融资余额3321.43万元，占流通市值的0.49%，融资 余额超过近一年50%分位水平，处于较高位。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年6月30日，春立医疗十大流通股东中，平安低碳经济混合A（009878）位居 第四大流通股东，持股377.00万股，相比上期增加277.00万股。南方医药保健灵活配置混合A （000452）位居第九大流通股东，持股160.30万股，为新进股东。中庚小盘价值股票（007130）、香港 中央结算有限公司、中庚价值先锋股票（012930）退出十大流通股东之列。 融券方面，春立医疗9月29日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量400.00股，融券余额 ...

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, is focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design inspection phase for customized dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021. The company specializes in the research, production, and sales of implantable orthopedic medical devices [7][8]. - The main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal implant products [8]. Business Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, with a year-on-year increase of 44.85% [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [9]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the evaluation of national small and medium-sized enterprises, indicating strong innovation capabilities and high market share [3]. - The company has introduced various types of 3D printing equipment for the development of customized prosthetic products, including EBM and MJF technologies [2]. Market Activity - On September 29, Spring Medical's stock fell by 1.25%, with a trading volume of 46.11 million yuan and a turnover rate of 0.68%, bringing the total market capitalization to 9.102 billion yuan [1]. - The stock's average trading cost is 21.06 yuan, with current price fluctuations between resistance at 25.20 yuan and support at 22.65 yuan, indicating potential for range trading [6].

9月25日，春立医疗涨1.09%，成交额7927.25万元。两融数据显示，当日春立医疗获融资买入额901.93 万元，融资偿还609.43万元，融资净买入292.50万元。截至9月25日，春立医疗融资融券余额合计 3071.78万元。 融资方面，春立医疗当日融资买入901.93万元。当前融资余额3070.81万元，占流通市值的0.44%，融资 余额低于近一年50%分位水平，处于较低位。 融券方面，春立医疗9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量400.00股，融券余额9624.00元，超过近一年80%分位水平，处于高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688236 证券简称：春立医疗 公告编号：2025-040 北京市春立正达医疗器械股份有限公司 关于与私募基金合作投资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、 与私募基金合作投资概述 北京市春立正达医疗器械股份有限公司（以下简称"公司"）与南昌德福投资咨询合伙企业（有限合伙） 及其他合伙人共同投资设立南昌德福四期股权投资基金合伙企业（有限合伙）（以下简称"合伙企 业"）。公司作为有限合伙人以自有资金5,000万元人民币参与认购合伙企业的份额，占基金份额的 9.2105%。具体内容详见公司于2025年8月8日在上海证券交易所网站（www.sse.com.cn）披露的《关于 与私募基金合作投资的公告》（公告编号：2025-033）。 执行事务合伙人：南昌德福投资咨询合伙企业 （有限合伙） 统一社会信用代码：91360125MAEC29JF22 出资额：伍亿肆仟贰佰捌拾伍万柒仟壹佰肆拾叁元整 企业类型：有限合伙企业 成立日期：2025年3月7日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於與私募基金合作投資的進展公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年9月25日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供 ...

Group 1 - The company, Chunli Medical, announced its investment in the establishment of the Nanchang Defu Phase IV Equity Investment Fund Partnership, contributing 50 million RMB as a limited partner, which represents 9.2105% of the fund's total shares [2] - The fund has completed the necessary business registration procedures and has obtained a business license from the Nanchang Market Supervision Administration [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 26.68 CNY, based on a 46 times PE valuation for 2025 [4][7]. Core Views - The company is expected to experience a turning point in performance as the impact of centralized procurement diminishes, with a projected revenue increase of 33.9% in 2025 [12]. - The company achieved a revenue of 4.9 billion CNY in the first half of 2025, representing a year-on-year growth of 28.3%, and a net profit of 1.1 billion CNY, up 44.9% year-on-year [12]. - The company is actively expanding its international market presence, with significant progress in obtaining CE and FDA approvals for its products, indicating strong international competitiveness [12]. Financial Summary - Revenue projections for 2025-2027 are 1,079 million CNY, 1,306 million CNY, and 1,578 million CNY, respectively, with corresponding growth rates of 33.9%, 21.0%, and 20.9% [6]. - The company's net profit for 2025 is forecasted at 224 million CNY, with a year-on-year growth of 79.4% [6]. - The gross margin is expected to stabilize around 67.5% in 2025, with a net margin of 20.8% [6].

证券代码：688236 证券简称：春立医疗 公告编号：2025-040 北京市春立正达医疗器械股份有限公司 关于与私募基金合作投资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 与私募基金合作投资概述 北京市春立正达医疗器械股份有限公司（以下简称"公司"）与南昌德福投资 咨询合伙企业（有限合伙）及其他合伙人共同投资设立南昌德福四期股权投资基 金合伙企业（有限合伙）（以下简称"合伙企业"）。公司作为有限合伙人以自 有资金 5,000 万元人民币参与认购合伙企业的份额，占基金份额的 9.2105%。具体 内容详见公司于 2025 年 8 月 8 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于与私募基金合作投资的公告》（公告编号：2025-033）。 二、与私募基金合作投资的进展情况 2025 年 9 月 25 日，公司收到基金管理人广州德福投资咨询合伙企业（有限合 伙）的通知，南昌德福四期股权投资基金合伙企业（有限合伙）已完成相关工商 登记手续并取得南昌市红谷滩区市场监督管理局颁发的《营 ...